$1.36
0.74% day before yesterday
Nasdaq, Jan 02, 10:00 pm CET
ISIN
US7530181004
Symbol
RANI

Rani Therapeutics Holdings Inc - Ordinary Shares Class A Stock price

$1.36
-0.02 1.45% 1M
+0.83 155.74% 6M
+0.01 0.74% YTD
-0.10 6.85% 1Y
-4.54 76.95% 3Y
-9.64 87.64% 5Y
-9.64 87.64% 10Y
-9.64 87.64% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
+0.01 0.74%
ISIN
US7530181004
Symbol
RANI
Industry

Key metrics

Basic
Market capitalization
$164.1m
Enterprise Value
$173.4m
Net debt
$9.4m
Cash
$4.1m
Shares outstanding
71.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
136.7 | 31.0
EV/Sales
144.5 | 32.8
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
5.4%
Return on Equity
-1,506.9%
ROCE
497.0%
ROIC
-
Debt/Equity
-1.7
Financials (TTM | estimate)
Revenue
$1.2m | $5.3m
EBITDA
$-43.8m | $-53.9m
EBIT
$-44.7m | $-37.5m
Net Income
$-28.3m | $-35.7m
Free Cash Flow
$-27.8m
Growth (TTM | estimate)
Revenue
- | 413.6%
EBITDA
13.9% | -10.9%
EBIT
13.6% | 24.3%
Net Income
-0.5% | -18.9%
Free Cash Flow
30.1%
Margin (TTM | estimate)
Gross
-
EBITDA
-3,646.1% | -1,018.1%
EBIT
-3,727.8%
Net
-2,359.6% | -674.8%
Free Cash Flow
-2,315.2%
More
EPS
$-0.6
FCF per Share
$-0.4
Short interest
13.6%
Employees
106
Rev per Employee
$10.0k
Show more

Is Rani Therapeutics Holdings Inc - Ordinary Shares Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Rani Therapeutics Holdings Inc - Ordinary Shares Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Rani Therapeutics Holdings Inc - Ordinary Shares Class A forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Rani Therapeutics Holdings Inc - Ordinary Shares Class A forecast:

Buy
89%
Hold
11%

Financial data from Rani Therapeutics Holdings Inc - Ordinary Shares Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
1.20 1.20
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 19 19
21% 21%
1,604%
- Research and Development Expense 23 23
16% 16%
1,914%
-44 -44
14% 14%
-3,646%
- Depreciation and Amortization 0.98 0.98
0% 0%
82%
EBIT (Operating Income) EBIT -45 -45
14% 14%
-3,728%
Net Profit -28 -28
1% 1%
-2,360%

In millions USD.

Don't miss a Thing! We will send you all news about Rani Therapeutics Holdings Inc - Ordinary Shares Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rani Therapeutics Holdings Inc - Ordinary Shares Class A Stock News

Neutral
GlobeNewsWire
about one month ago
SAN JOSE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company's management team will participate in the upcoming Evercore Healthcare Conference. Details below:
Neutral
GlobeNewsWire
about 2 months ago
– Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics –
Neutral
GlobeNewsWire
2 months ago
SAN JOSE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill® capsule, the company's oral delivery platform, at ObesityWeek® 2025 taking place both virtually and...
More Rani Therapeutics Holdings Inc - Ordinary Shares Class A News

Company Profile

Rani Therapeutics Holdings, Inc. operates as a clinical stage bio-therapeutics company providing technologies to enable the development of orally administered biologics. It offers RaniPill capsule, an orally ingestible pill for the administration of a broad range of biologics. The company was founded by Mir Imran on April 6, 2021 and is headquartered in San Jose, CA.

Head office United States
CEO Talat Imran
Employees 106
Founded 2012
Website www.ranitherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today